MeghaBhumralkar Ph.D.

Patent Agent

Los Angeles +

Megha Bhumralkar is a registered patent agent with more than 20 years of experience in developing and managing patent portfolios in the areas of pharmaceuticals, biotechnology, chemistry, and the food industry. She has drafted and prosecuted patent applications for small molecule pharmaceuticals, drug conjugates, and formulations in patent portfolios covering clinical candidates and approved products for several biotechnology and pharmaceutical companies. Representative clients include Bristol Myers Squibb, Daiichi Sankyo, Biogen, Acorda Pharmaceuticals, Bunge Limited, and academic institutions. Particular small molecule pharmaceuticals that Megha has been involved with include, IDHIFA®, THELIN®, Quizartinib, Eragidomide, Emricasan, and Vosaroxin.

In addition to patent procurement and portfolio management, Megha advises clients regarding patentability, Orange Book listing, patent life cycle management, validity, infringement, and freedom-to-operate issues; and she performs due diligence evaluations of patent portfolios for possible licensing or acquisition.

Before joining Jones Day, Megha was a technology specialist in the San Diego offices of several IP-centered law firms. Prior to entering the intellectual property field, she was a postdoctoral research fellow at the University of California, San Diego where her research involved synthetic collagen mimetics. She worked extensively on small molecule heterocycles during her graduate studies.


  • MEI Pharma develops patent portfolio for small molecule PI3K delta inhibitorsJones Day represents MEI Pharma, Inc. in patent prosecution of small molecule PI3K delta inhibitors.
  • Ambit Biosciences develops patent portfolio for small molecule kinase inhibitor programsJones Day represented Ambit Biosciences in the development of patent portfolios related to small molecule kinase inhibitor programs and phage-displayed protein assays.